Differences in the Effectiveness of Single, Dual, and Triple Inhaled Corticosteroid Therapy for Reducing Future Risk of Severe Asthma Exacerbation: A Systematic Review and Network Meta-analysis

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Jul 18

PMID 39022061

Authors

Akira Yamasaki

Katsuyuki Tomita

Genki Inui

Ryota Okazaki

Tomoya Harada

Affiliations

Soon will be listed here.

Abstract

Importance: The effectiveness of different combinations of inhaled corticosteroid (ICS) therapies in reducing severe exacerbations of adult asthma remains unclear.

Objective: This network meta-analysis (NMA) extensively evaluated the treatment effects of single ICS; dual ICS i.e., ICS/long-acting β2-adrenergic agonists (LABA); ICS/LABA as single maintenance and reliever therapy (SMART); and triple ICS, i.e., ICS/LABA/long-acting muscarinic antagonists (LAMA) in preventing severe asthma exacerbations.

Data Sources: A systematic search of English databases, including PubMed and Web of Science, was conducted until December 31, 2022, using PRISMA-NMA.

Study Selection: Using the PICOS criteria, the questions for this study were carefully selected so that the correct keywords could be identified.

Data Extraction And Synthesis: A pairwise meta-analysis was used to select trials based on the criteria for minimizing heterogeneity (I). Subsequently, the "BUGSnet" package of R software was used to perform a Bayesian network meta-analysis.

Main Outcome Measures: The main outcome measures were risk rate and annualized rate ratio of severe asthma exacerbations.

Results: This review included 56 randomized control trials (RCTs; n = 78,171 patients). As the pairwise meta-analysis demonstrated that the annualized rate ratio of severe asthma exacerbation had moderate heterogeneity, we analyzed the risk rate of severe asthma exacerbation using a network meta-analysis. In terms of direct/indirect comparisons with non-ICS, single ICS, dual ICS, SMART, and triple ICS reduced severe asthma exacerbations by 34 %, 47 %, 58 %, and 57 %, respectively. SMART and triple ICS showed high effectiveness in reducing severe exacerbations.

Conclusion: AND RELEVANCE: SMART and triple ICS were ranked higher in effectiveness in reducing severe asthma exacerbations in comparison with other therapies, indicating that these are the most effective treatments for reducing the future risk of severe asthma exacerbations.

Citing Articles

Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).

Baptist A, Germain G, Klimek J, Laliberte F, Schell R, Forero-Schwanhaeuser S Adv Ther. 2024; 42(2):1061-1074.

PMID: 39714547 PMC: 11787182. DOI: 10.1007/s12325-024-03083-6.

References

Willey R, Godden D, Carmichael J, Preston P, Frame M, Crompton G . Comparison of twice daily administration of a new corticosteroid budesonide with beclomethasone dipropionate four times daily in the treatment of chronic asthma. Br J Dis Chest. 1982; 76(1):61-8. View

Peters S, Bleecker E, Canonica G, Park Y, Ramirez R, Hollis S . Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. N Engl J Med. 2016; 375(9):850-60. DOI: 10.1056/NEJMoa1511190. View

Riemersma R, Postma D, van der Molen T . Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Prim Care Respir J. 2011; 21(1):50-6. PMC: 6548307. DOI: 10.4104/pcrj.2011.00090. View

Meltzer E, Kuna P, Nolte H, Nayak A, Laforce C . Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J. 2011; 39(2):279-89. DOI: 10.1183/09031936.00020310. View

Chipps B, Taylor B, Bayer V, Shaikh A, Mosnaim G, Trevor J . Relative efficacy and safety of inhaled corticosteroids in patients with asthma: Systematic review and network meta-analysis. Ann Allergy Asthma Immunol. 2020; 125(2):163-170.e3. DOI: 10.1016/j.anai.2020.04.006. View

Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K . Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991; 325(6):388-92. DOI: 10.1056/NEJM199108083250603. View

Reddel H, Belousova E, Marks G, Jenkins C . Does continuous use of inhaled corticosteroids improve outcomes in mild asthma? A double-blind randomised controlled trial. Prim Care Respir J. 2008; 17(1):39-45. PMC: 6619862. DOI: 10.3132/pcrj.2008.00014. View

Meltzer E, Busse W, Wenzel S, Belozeroff V, Weng H, Feng J . Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol. 2010; 127(1):167-72. DOI: 10.1016/j.jaci.2010.08.042. View

Bateman E, Reddel H, OByrne P, Barnes P, Zhong N, Keen C . As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018; 378(20):1877-1887. DOI: 10.1056/NEJMoa1715275. View

10.

OByrne P, FitzGerald J, Bateman E, Barnes P, Zhong N, Keen C . Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med. 2018; 378(20):1865-1876. DOI: 10.1056/NEJMoa1715274. View

11.

Gelb A, Flynn Taylor C, Shinar C, Gutierrez C, Zamel N . Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest. 2006; 129(6):1492-9. DOI: 10.1378/chest.129.6.1492. View

12.

Oba Y, Anwer S, Maduke T, Patel T, Dias S . Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2022; 12:CD013799. PMC: 9723963. DOI: 10.1002/14651858.CD013799.pub2. View

13.

Amir-Behghadami M, Janati A . Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020; 37(6):387. DOI: 10.1136/emermed-2020-209567. View

14.

Quirce S, Barcina C, Plaza V, Calvo E, Munoz M, Ampudia R . A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. J Asthma. 2011; 48(8):839-47. DOI: 10.3109/02770903.2011.611954. View

15.

FitzGerald J, Sadatsafavi M . Triple therapy in a single inhaler: a new option for uncontrolled asthma. Lancet. 2019; 394(10210):1690-1692. DOI: 10.1016/S0140-6736(19)32216-0. View

16.

Papi A, Chipps B, Beasley R, Panettieri Jr R, Israel E, Cooper M . Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. N Engl J Med. 2022; 386(22):2071-2083. DOI: 10.1056/NEJMoa2203163. View

17.

Clark T . Effect of beclomethasone dipropionate delivered by aerosol in patients with asthma. Lancet. 1972; 1(7765):1361-4. DOI: 10.1016/s0140-6736(72)91094-x. View

18.

Kerstjens H, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M . Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012; 367(13):1198-207. DOI: 10.1056/NEJMoa1208606. View

19.

Stallberg B, Olsson P, Jorgensen L, Lindarck N, Ekstrom T . Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract. 2003; 57(8):656-61. View

20.

Bateman E, Hurd S, Barnes P, Bousquet J, Drazen J, Fitzgerald J . Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008; 31(1):143-78. DOI: 10.1183/09031936.00138707. View